TrialESMO open2025

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.

J-P Metges et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.